OncoMatch/Clinical Trials/NCT06644755
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Is NCT06644755 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DS-2243a for solid tumors.
Treatment: DS-2243a — This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Sarcoma
Biomarker criteria
Required: HLA-A positive for HLA-A*02:01, 02:02, 02:03, 02:04, 02:05, 02:06, 02:09, 02:10, or 02:11
HLA-A*02:01, 02:02, 02:03, 02:04, 02:05, 02:06, 02:09, 02:10, or 02:11 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: appropriate therapies (e.g., standard of care therapy)
Relapsed from, refractory to, or intolerant to appropriate therapies [eg, standard of care (SOC) therapy] to provide clinical benefit for their condition as assessed by their physician and/or investigator.
Cannot have received: NY-ESO-1-targeted therapy
Has received prior therapy targeting NY-ESO-1.
Lab requirements
Blood counts
ANC ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥8 g/dL
Kidney function
Creatinine clearance (CrCl) ≥45 mL/min as calculated using the Cockcroft-Gault equation
Liver function
ALT and AST ≤3 × ULN in participants with no liver metastasis, or ≤5 × ULN in participants with liver metastasis; Total bilirubin ≤1.5 × ULN (≤3 × ULN for participants with Gilbert's syndrome)
Meets the following required baseline local laboratory data within 14 days prior to start of trial intervention administration: ALT and AST ≤3 × ULN in participants with no liver metastasis, or ≤5 × ULN in participants with liver metastasis; Total bilirubin ≤1.5 × ULN (≤3 × ULN for participants with Gilbert's syndrome); ANC ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥8 g/dL; Creatinine clearance (CrCl) ≥45 mL/min as calculated using the Cockcroft-Gault equation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, New York
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify